Home / Deep Research / Disorder of Catecholamine Synthesis

Disorder of Catecholamine Synthesis

1. Disease Information

2026-05-08
Falcon MONDO:0017759 Model: Edison Scientific Literature 36 citations

1. Disease Information

1.1 Concise overview

Inherited disorders within this umbrella cause dopamine and other catecholamine deficiencies (norepinephrine, epinephrine) in the CNS and/or periphery due to defects in: - Biosynthesis enzymes (e.g., TH, AADC), - Cofactor pathways (BH4), - Associated transport/catabolism pathways (group-level differential diagnosis), - Or enzyme stability (DNAJC12 co‑chaperone).

They are rare neurodevelopmental diseases with predominant neurologic manifestations such as movement disorders, autonomic dysfunction, and developmental delay. (hubschmann2021insightsintothe pages 1-2, chu2024genetherapyfor pages 1-2)

1.2 Synonyms / alternative names (examples)

Because this is an umbrella, synonyms vary by subdisorder; key included entities: - AADC deficiency / Aromatic L‑amino acid decarboxylase deficiency / DDC deficiency. (paola2024aromaticlaminoacid pages 2-3) - Tyrosine hydroxylase deficiency (THD); overlaps with dopa‑responsive dystonia spectrum. (reyes2023diagnosisofautism pages 1-2) - BH4 deficiency disorders (BH4 biosynthesis/recycling defects leading to monoamine neurotransmitter deficiency ± hyperphenylalaninemia). (nezhad2024genotypicvariantsof pages 1-2) - Autosomal recessive GTP cyclohydrolase I deficiency (arGTPCH; recessive GCH1). (novelli2024autosomalrecessiveguanosine pages 1-2)

1.3 Evidence provenance

Evidence here is derived from: - Aggregated resources/registries (iNTD registry of 275 patients). (hubschmann2021insightsintothe pages 1-2) - Peer‑reviewed cohort/screening studies (e.g., Sicilian carrier screening for DDC). (paola2024aromaticlaminoacid pages 1-2) - Case reports (TH deficiency). (reyes2023diagnosisofautism pages 1-2) - Clinical trial registries and implementation reports for gene therapy. (NCT01395641 chunk 1, NCT04903288 chunk 1, mai2025framelessintraputaminaldelivery pages 1-2)

2. Etiology

2.1 Disease causal factors (primary)

Genetic: Pathogenic variants in genes encoding enzymes/cofactors required for catecholamine synthesis. - TH encodes tyrosine hydroxylase, which converts L‑tyrosine → L‑DOPA (rate-limiting step). (reyes2023diagnosisofautism pages 1-2) - DDC encodes AADC, which converts L‑DOPA → dopamine and 5‑HTP → serotonin, causing combined monoamine deficiency when impaired. (paola2024aromaticlaminoacid pages 1-2) - BH4-pathway genes (GCH1, PTS, QDPR, SPR, PCBD1) cause monoamine deficiency by limiting the BH4 cofactor required by TH and tryptophan hydroxylase, and can also cause hyperphenylalaninemia due to PAH impairment. (nezhad2024genotypicvariantsof pages 1-2) - DNAJC12 encodes a co‑chaperone for aromatic amino acid hydroxylases and interacts with TH/TPH/GCH1; biallelic variants cause a combined phenotype including monoamine deficiency. (deng2025centralbiogenicamine pages 1-2, deng2024dnajc12inmonoamine pages 1-5)

2.2 Risk factors

For inherited disorders, major risk factors are: - Family history and parental carrier status for autosomal recessive forms. (nezhad2024genotypicvariantsof pages 1-2) - Consanguinity increases incidence of BH4 deficiency in high-consanguinity regions, as emphasized in the Iranian BH4 gene-variant cohort. (nezhad2024genotypicvariantsof pages 1-2)

2.3 Protective factors

No robust protective environmental/genetic factors were identified in the retrieved evidence for the umbrella category.

2.4 Gene–environment interactions

Not established in the retrieved corpus for these rare Mendelian conditions.

3. Phenotypes (clinical features)

3.1 Cross-cutting phenotype patterns

The iNTD registry describes inherited biogenic amine disorders as rare neurodevelopmental diseases with movement disorders and global developmental delay, often presenting with nonspecific early symptoms and diagnostic delay. (hubschmann2021insightsintothe pages 1-2) Typical monoamine-related phenotypes include neonatal hypotonia, dystonia, parkinsonism, oculogyric crises, autonomic dysfunction and developmental delay. (chu2024genetherapyfor pages 1-2)

3.2 AADC (DDC) deficiency phenotypes and onset

AADC deficiency usually presents within the first months of life with: - Hypotonia, oculogyric crises, dystonia/hypokinesia, developmental delay, autonomic dysfunction and GI symptoms. (paola2024aromaticlaminoacid pages 1-2) Sentieri’s newborn-screening–oriented summary reports early onset and marked diagnostic delay: mean onset ~2.7 months and mean diagnosis ~3.5 years (secondary source within retrieved corpus). (sentieri2023analisideilivelli pages 21-25)

Quality of life impact: severe impairment of motor milestones and complications such as feeding difficulties, reflux/aspiration, contractures, scoliosis/hip dysplasia are highlighted in the rehabilitation position statement. (lee2024apositionstatement pages 1-2)

3.3 TH deficiency phenotypes and onset

TH deficiency is a rare autosomal recessive movement disorder caused by biallelic TH variants. It is part of the dopa‑responsive dystonia spectrum with phenotypes ranging from: 1) TH-deficient dopa-responsive dystonia, 2) TH-deficient infantile parkinsonism with motor delay, 3) TH-deficient progressive infantile encephalopathy. (reyes2023diagnosisofautism pages 1-2) The 2023 case report describes hypotonia and motor/speech delay in a ~3-year-old child, with excellent response to carbidopa–levodopa. (reyes2023diagnosisofautism pages 1-2)

3.4 BH4 deficiency disorders (group) phenotypes

BH4 deficiencies can produce systemic hyperphenylalaninemia plus CNS monoamine deficiency leading to neurological consequences (developmental problems, seizures, intellectual disability, movement disorders). (nezhad2024genotypicvariantsof pages 1-2)

3.5 Suggested HPO terms (non-exhaustive)

(Provided as ontology suggestions; not directly extracted from source texts.) - Hypotonia (HP:0001252) - Developmental delay (HP:0001263) - Dystonia (HP:0001332) - Parkinsonism (HP:0001300) - Oculogyric crisis (HP:0002173) - Autonomic dysfunction (HP:0002270) - Feeding difficulties (HP:0011968) - Seizures (HP:0001250)

4. Genetic/Molecular Information

4.1 Causal genes (core set supported in retrieved evidence)

4.2 Pathway and biochemical roles (key concepts)

The gene-therapy review of neurotransmitter-related disorders summarizes monoamine biosynthesis: dopamine is made from L‑tyrosine by TH (BH4-dependent) then by AADC (PLP-dependent), and synaptic DA handling involves DAT/VMAT2. (chu2024genetherapyfor pages 1-2)

The extracted pathway figure from Roubertie et al. provides a visual schematic of monoamine synthesis and is appropriate to cite for pathway representation. (roubertie2024genetherapyfor media e0e2cf3d)

4.3 DNAJC12 mechanistic insight (model organism + human phenotype)

The 2025 NPJ Parkinson’s Disease paper provides mechanistic support that DNAJC12 interacts with TH/TPH/GCH1 and that loss destabilizes a DNAJC12–TH–GCH1 complex; Dnajc12 knockout mice show reduced striatal dopamine and serotonin and exploratory behavioral deficits. (deng2025centralbiogenicamine pages 1-2, deng2025centralbiogenicamine pages 2-4) The 2024 Movement Disorders review summarizes that DNAJC12 pathogenic variants can cause mild hyperphenylalaninemia with infantile dystonia, young‑onset parkinsonism, developmental delay, and cognitive deficits, and notes incorporation of DNAJC12 into newborn screening programs (Spain). (deng2024dnajc12inmonoamine pages 1-5)

4.4 Suggested GO and CL terms (non-exhaustive)

(Provided as ontology suggestions.) - Dopamine biosynthetic process (GO:0042417) - Catecholamine biosynthetic process (GO:0042423) - Tetrahydrobiopterin biosynthetic process (GO:0006729) - Tyrosine hydroxylase activity (GO:0004507) - Aromatic L-amino acid decarboxylase activity (GO:0004059) - Dopaminergic neuron (CL:0000700) - Noradrenergic neuron (CL:0000820) - Serotonergic neuron (CL:0000850)

5. Environmental Information

No specific environmental exposures causing the inherited enzyme/cofactor defects were identified in the retrieved corpus; however, environmental context is relevant for screening false positives in AADC newborn screening (e.g., maternal dopaminergic medications may elevate DBS 3‑OMD). (sentieri2023analisideilivelli pages 21-25)

6. Mechanism / Pathophysiology

6.1 Causal chain (AADC deficiency as exemplar)

DDC loss-of-function → reduced AADC activity → reduced dopamine + serotonin synthesis → downstream reduced norepinephrine/epinephrine → motor dysfunction + autonomic dysfunction + developmental delay; with accumulation of upstream metabolites (notably 3‑O‑methyldopa/3‑OMD). (paola2024aromaticlaminoacid pages 1-2, sentieri2023analisideilivelli pages 21-25)

6.2 Key biochemical abnormalities and biomarkers

  • AADC deficiency CSF signature: low 5‑HIAA, HVA, and MHPG; elevated 3‑OMD, L‑DOPA and 5‑OH tryptophan; normal pterins. (paola2024aromaticlaminoacid pages 1-2)
  • AADC newborn screening biomarker: markedly elevated DBS 3‑OMD; Sentieri reports mean patient DBS 3‑OMD ~1,113 ng/mL (range 530–2,430 ng/mL) and gives population newborn levels far lower (study-dependent); the same source notes large-cohort screening and incidence inference in Taiwan. (sentieri2023analisideilivelli pages 21-25)
  • TH deficiency: TH catalyzes the rate‑limiting step in catecholamine synthesis; TH deficiency phenotypes reflect dopamine and downstream catecholamine deficiency and can respond to levodopa. (reyes2023diagnosisofautism pages 1-2)

6.3 Gene therapy mechanism (AADC)

AADC gene therapy uses a recombinant AAV vector carrying human DDC (hAADC) delivered stereotactically to the putamen to restore AADC activity locally in basal ganglia circuits. (roubertie2024genetherapyfor pages 4-4, NCT04903288 chunk 1) The extracted schematic figure can be cited for vector/delivery conceptualization. (roubertie2024genetherapyfor media d99c2658)

7. Anatomical Structures Affected

7.1 Primary systems

Predominantly central nervous system, with motor and neurodevelopmental phenotypes, plus systemic autonomic manifestations. (hubschmann2021insightsintothe pages 1-2, chu2024genetherapyfor pages 1-2)

7.2 Key neuroanatomical targets in therapy/biomarkers

Suggested UBERON terms (non-exhaustive): - Putamen (UBERON:0001874) - Basal ganglion (UBERON:0002420) - Brain (UBERON:0000955)

8. Temporal Development

8.1 Onset

8.2 Progression/course

The iNTD registry indicates phenotypes range from mild hypotonia and late-onset movement disorders to early-onset lethal encephalopathies, and diagnostic delay has decreased in recent years. (hubschmann2021insightsintothe pages 1-2)

9. Inheritance and Population

9.1 Inheritance patterns

9.2 Epidemiology highlights (recent evidence)

10. Diagnostics

10.1 Core diagnostic approach (umbrella)

10.2 AADC deficiency biomarkers (recommended)

10.3 TH deficiency diagnostics

TH deficiency diagnosis is suggested by biochemical neurotransmitter patterns (e.g., low CSF HVA) and confirmed by biallelic TH variants; clinical response to levodopa can be prominent. (reyes2023diagnosisofautism pages 1-2)

10.4 Differential diagnosis (high level)

Inherited biogenic amine disorders include biosynthesis, catabolism, transport, BH4, and co-chaperone defects; thus differential diagnosis spans multiple gene classes beyond “catecholamine synthesis” alone. (hubschmann2021insightsintothe pages 1-2)

11. Outcome / Prognosis

11.1 Prognosis without disease-modifying therapy

The iNTD registry notes some disorders can manifest as early-onset severe encephalopathies, while others are milder; misdiagnosis and delayed diagnosis are common. (hubschmann2021insightsintothe pages 1-2)

11.2 Gene therapy outcomes in AADC deficiency

The rehabilitation position statement summarizes that after eladocagene exuparvovec, motor improvements can be observed as early as 3 months; PDMS‑2 and AIMS gains can persist over years, with some patients walking independently within ~3 years, and common events include fever and transient dyskinesia. (lee2024apositionstatement pages 1-2)

12. Treatment

12.1 Pharmacotherapy (supportive/symptomatic and pathway-based)

A diagnostic/treatment overview (Kulhánek) describes general neurotransmitter-disorder strategies: - Precursor replacement (L‑DOPA with peripheral decarboxylase inhibitor; and serotonin pathway precursors), - Dopamine agonists (e.g., pramipexole), - MAO‑B inhibitors (e.g., selegiline), - BH4 analog supplementation (sapropterin) and Phe control in HPA-related disorders, - Vitamin B6 supplementation and multidisciplinary supportive care. (kulhanek2026studyofdiagnostica pages 46-49)

12.2 Disease-modifying therapy: AADC gene therapy (eladocagene exuparvovec)

  • Regulatory milestone: EU approval July 2022 for severe AADC deficiency (summarized in first-approval review and in disease-specific papers). (paola2024aromaticlaminoacid pages 2-3)
  • Expert implementation guidance: iNTD Delphi recommendations emphasize a quality-assured framework, specialized multidisciplinary centers, and structured long-term follow-up/registry documentation due to limited comparative long-term data. (roubertie2024genetherapyfor pages 3-3)
  • Post-treatment rehabilitation expert opinion: a 2024 position statement provides pragmatic rehab recommendations to maximize functional gains after gene therapy. (lee2024apositionstatement pages 1-2)

12.3 Clinical trials (selected; gene therapy)

Key AADC gene therapy trials and endpoints: - NCT01395641 (AAV2-hAADC, bilateral putamen; Phase I/II; completed; n=10). Primary endpoints include increase in CSF HVA or 5‑HIAA and >10-point PDMS‑II improvement at 12 months. Start 2014-10-22; completion 2022-03-07. (NCT01395641 chunk 1) - NCT04903288 (eladocagene exuparvovec delivered with SmartFlow MR-compatible cannula; Phase 2; includes CSF HVA primary endpoint at Week 8; includes PET, PDMS‑2, Bayley‑III, EQ‑5D‑Y). Start 2021-05-12; results posted 2025-01-01. (NCT04903288 chunk 1) - NCT05765981 (VGN‑R09b AAV9-hAADC; Early Phase 1; recruiting; bilateral putamen injection; primary safety and PDMS-II milestone ratio at Week 52). Start 2023-01-30. (NCT05765981 chunk 1) - NCT02852213 (AAV2-hAADC delivered to midbrain targets SNc/VTA; Phase 1; recruiting; includes CSF metabolites and motor scales). Start 2016-07-01. (NCT02852213 chunk 1)

12.4 Suggested MAXO terms (examples)

(Provided as ontology suggestions.) - Levodopa therapy (MAXO:0000139) - Dopamine agonist therapy (MAXO:0000153) - Monoamine oxidase inhibitor therapy (MAXO:0000191) - Gene therapy (MAXO:0000010) - Newborn screening (MAXO:0000796) - Physical therapy (MAXO:0000012) - Occupational therapy (MAXO:0000013)

13. Prevention

13.1 Secondary prevention: newborn screening

14. Other Species / Natural Disease

No naturally occurring non-human disease analogs were identified in the retrieved evidence for catecholamine synthesis disorders specifically.

15. Model Organisms

A mechanistically informative model organism for the broader umbrella is the Dnajc12 knock-out mouse, which shows reduced striatal dopamine/serotonin and exploratory behavioral deficits, providing an experimental platform for therapeutic development in biogenic amine disorders. (deng2025centralbiogenicamine pages 1-2, deng2025centralbiogenicamine pages 2-4)

Key concepts and definitions (consolidated)

Recent developments and real-world implementation highlights (2023–2024 prioritized)

Statistics and data (recent studies)

Evidence-backed abstract quotes (selected)

  • AADC (Genes 2024) abstract: “Aromatic L-amino acid decarboxylase deficiency (AADCd) is a rare autosomal recessive neurometabolic disorder caused by AADC deficiency, an enzyme encoded by the DDC gene.” and “Taiwan is the site of a potential founder variant (IVS6+4A>T) with a predicted incidence of 1/32,000 births…” (Paola et al., 2024-01; https://doi.org/10.3390/genes15010134) (paola2024aromaticlaminoacid pages 1-2)
  • AADC rehabilitation position statement (Orphanet 2024) abstract: “The approval of eladocagene exuparvovec, a gene therapy for AADC deficiency with demonstrated efficacy for motor improvements, now expands the range of motor outcomes possible for patients with this disorder.” (Lee et al., 2024-01; https://doi.org/10.1186/s13023-024-03019-x) (lee2024apositionstatement pages 1-2)
  • Gene therapy for neurotransmitter disorders (JIMD 2024) abstract: “Along with the recent European Medicines Agency (EMA) and Medicines and Healthcare Products Regulatory Agency (MHRA) approval of an AAV2 gene supplementation therapy for AADC deficiency, promising efficacy and safety profiles can be achieved in this group of diseases.” (Chu et al., 2024-01; https://doi.org/10.1002/jimd.12697) (chu2024genetherapyfor pages 1-2)
  • BH4 gene-variant cohort (MGGM 2024) abstract: “The subsequent systemic hyperphenylalaninemia and monoamine neurotransmitter deficiency lead to neurological consequences.” (Nezhad et al., 2024-10; https://doi.org/10.1002/mgg3.2294) (nezhad2024genotypicvariantsof pages 1-2)
  • DNAJC12 review (Movement Disorders 2024) abstract: “Recent studies show that pathogenic variants in DNAJC12… may cause mild hyperphenylalaninemia with infantile dystonia, young-onset parkinsonism, developmental delay and cognitive deficits.” (Deng et al., 2024-11; https://doi.org/10.1002/mds.29677) (deng2024dnajc12inmonoamine pages 1-5)
  • Dnajc12 KO mouse (npj Parkinson’s Disease 2025) abstract: “Bi-allelic autosomal recessive pathogenic variants in DNAJC12 lead to a constellation of neurological features, including young-onset Parkinson’s disease. DNAJC12 is a co-chaperone for enzymes involved in biogenic amines synthesis.” (Deng et al., 2025-05; https://doi.org/10.1038/s41531-025-00991-4) (deng2025centralbiogenicamine pages 2-4)

Visual evidence (pathway and vector schematic)

The monoamine/catecholamine synthesis pathway schematic and the AADC gene therapy vector/delivery schematic were extracted from Roubertie et al. 2024. (roubertie2024genetherapyfor media e0e2cf3d, roubertie2024genetherapyfor media d99c2658)

Structured gene/phenotype scaffold

Table (click to expand)
Disorder (umbrella) Causal gene(s) Enzyme/cofactor role in pathway Typical biochemical signature (CSF/DBS where available) Key clinical features Inheritance Notable epidemiology stats Key references (with URLs, dates) Evidence context IDs
Aromatic L-amino acid decarboxylase (AADC) deficiency DDC AADC converts L-DOPA → dopamine and 5-HTP → serotonin; downstream deficiency also lowers norepinephrine/epinephrine CSF: low HVA, low 5-HIAA, low MHPG; high 3-OMD, L-DOPA, 5-HTP; normal pterins. DBS/newborn screening: elevated 3-OMD Infantile onset; hypotonia, oculogyric crises, dystonia/hypokinesia, developmental delay, autonomic dysfunction, feeding/GI symptoms, sleep/behavior problems; severe and mild/moderate phenotypes reported Autosomal recessive Taiwan founder variant associated with predicted incidence ~1/32,000 births; one 2024 review noted 261 reported patients globally and Sicilian neurological cohort carrier frequency 2.57% Paola et al., Genes (2024-01), https://doi.org/10.3390/genes15010134 ; Roubertie et al., J Inherit Metab Dis (2024-07), https://doi.org/10.1002/jimd.12649 ; Lee et al., Orphanet J Rare Dis (2024-01), https://doi.org/10.1186/s13023-024-03019-x (paola2024aromaticlaminoacid pages 2-3, lee2024apositionstatement pages 1-2, paola2024aromaticlaminoacid pages 1-2, roubertie2024genetherapyfor pages 4-4)
Tyrosine hydroxylase deficiency (THD) TH TH catalyzes tyrosine → L-DOPA, the rate-limiting step in catecholamine synthesis; requires BH4 Diagnosis suggested by low CSF HVA and confirmed by biallelic TH variants; 3-OMD may be low/reduced as surrogate of reduced TH activity in CSF workflows Spectrum from dopa-responsive dystonia to infantile parkinsonism and progressive infantile encephalopathy; hypotonia, dystonia/parkinsonism, motor delay; some patients improve markedly with carbidopa/levodopa Autosomal recessive Reported prevalence for dopa-responsive dystonias/THD spectrum ~0.5–1 per million (likely underestimated) Reyes et al., BMC Med Genomics (2023-04), https://doi.org/10.1186/s12920-023-01510-1 ; Bondarenko et al., J Inherit Metab Dis (2025-11), https://doi.org/10.1002/jimd.70106 (reyes2023diagnosisofautism pages 1-2)
Autosomal recessive GTP cyclohydrolase I deficiency (BH4 deficiency subtype) GCH1 GTPCH catalyzes the first/rate-limiting step in BH4 biosynthesis; BH4 is required for TH and tryptophan hydroxylase, affecting dopamine, norepinephrine, epinephrine, serotonin synthesis Gradient of BH4 biochemical defect by phenotype; hyperphenylalaninemia common in severe early-infantile forms and absent in later dystonia-parkinsonism/DRD groups; abnormal biogenic amines/pterins support diagnosis Three described phenotypes: early-infantile encephalopathic, dystonia-parkinsonism with developmental stagnation/regression, and late-onset dopa-responsive dystonia; early treatment improves outcome Autosomal recessive UltraraRE; pooled series 45 patients in 2024 review. For comparison, dominant GCH1 deficiency prevalence estimated ~0.5–1.0/million Novelli et al., Mov Disord Clin Pract (2024-07), https://doi.org/10.1002/mdc3.14157 (novelli2024autosomalrecessiveguanosine pages 1-2)
BH4 biosynthesis/recycling disorders (group umbrella) PTS, QDPR, SPR, PCBD1 (also BH4-related GCH1) BH4 synthesis/recycling enzymes maintain tetrahydrobiopterin, the essential cofactor for TH, tryptophan hydroxylase, and PAH; deficiency causes monoamine neurotransmitter deficiency ± hyperphenylalaninemia Group features include abnormal pterins, HPA in many subtypes, and CSF monoamine abnormalities (low HVA/5-HIAA expected in BH4-related monoamine deficiency). Blood Phe alone does not distinguish PAH from BH4 disorders Neurodevelopmental delay, intellectual disability, seizures, movement disorder, depletion of brain dopamine/serotonin/norepinephrine; some disorders detected by newborn screening because they present with HPA Usually autosomal recessive HPA prevalence examples reported in 2024 review: China 1/15,415, Japan 1/143,000, Turkey ~1:2,600, pooled estimates ~38–43.3/100,000; consanguinity increases BH4-deficiency incidence in some regions Nezhad et al., Mol Genet Genomic Med (2024-10), https://doi.org/10.1002/mgg3.2294 (nezhad2024genotypicvariantsof pages 1-2)
6-pyruvoyl-tetrahydropterin synthase deficiency PTS PTPS is a core BH4 biosynthesis enzyme upstream of catecholamine/serotonin synthesis Typically BH4-deficiency pattern with HPA, abnormal pterins, and monoamine deficiency on CSF neurotransmitter studies Developmental delay, seizures, movement disorder, monoamine deficiency symptoms; mild forms may respond relatively well to treatment Autosomal recessive 2024 variant review listed ~199 PTS variants in PNDdb Nezhad et al., Mol Genet Genomic Med (2024-10), https://doi.org/10.1002/mgg3.2294 (nezhad2024genotypicvariantsof pages 1-2)
Dihydropteridine reductase deficiency QDPR DHPR regenerates BH4 from quinonoid dihydrobiopterin; failure impairs catecholamine/serotonin synthesis and PAH function BH4-deficiency pattern with HPA, abnormal pterins, and CSF monoamine deficiency; folate disturbance may be clinically relevant in DHPR deficiency management literature Developmental delay, seizures, movement disorder, monoamine deficiency; neurologic consequences reflect dopamine/serotonin/norepinephrine depletion Autosomal recessive 2024 variant review listed ~141 QDPR variants in PNDdb Nezhad et al., Mol Genet Genomic Med (2024-10), https://doi.org/10.1002/mgg3.2294 (nezhad2024genotypicvariantsof pages 1-2)
Sepiapterin reductase deficiency SPR SR catalyzes a late BH4 biosynthesis step; deficiency impairs dopamine/serotonin synthesis and may occur without marked HPA Typically a BH4/monoamine deficiency phenotype; pterin/CSF neurotransmitter testing is important because blood phenylalanine alone may miss non-HPA BH4 disorders Developmental delay, dystonia/parkinsonism, oculogyric crises, other neurotransmitter-deficiency manifestations Autosomal recessive 2024 variant review listed ~104 SPR variants in PNDdb Nezhad et al., Mol Genet Genomic Med (2024-10), https://doi.org/10.1002/mgg3.2294 (nezhad2024genotypicvariantsof pages 1-2)
Pterin-4α-carbinolamine dehydratase deficiency PCBD1 PCD/PCBD1 functions in BH4 recycling Usually identified in BH4-deficiency/HPA workup with abnormal pterin profile; molecular confirmation required because blood Phe is nonspecific Can contribute to BH4-related HPA and monoamine deficiency spectrum; clinical severity variable Autosomal recessive 2024 variant review listed ~32 PCBD1 variants in PNDdb Nezhad et al., Mol Genet Genomic Med (2024-10), https://doi.org/10.1002/mgg3.2294 (nezhad2024genotypicvariantsof pages 1-2)
DNAJC12-related monoamine synthesis disorder DNAJC12 DNAJC12 is a co-chaperone for enzymes involved in monoamine synthesis, including interaction with TH and GCH1; destabilization impairs dopamine/serotonin biosynthesis May present with mild HPA plus central biogenic amine deficiency; mechanism supported by reduced striatal dopamine/serotonin in knockout models and impaired TH/GCH1 complex stability Infantile dystonia, developmental delay, cognitive deficits, young-onset parkinsonism; emphasizes importance of early genetic diagnosis and intervention Autosomal recessive Included in newborn screening in some regions (e.g., Spain, per 2024 review); many adult patients may still be undiagnosed Deng et al., Movement Disorders (2024-11), https://doi.org/10.1002/mds.29677 ; Deng et al., npj Parkinsons Dis (2025-05), https://doi.org/10.1038/s41531-025-00991-4 (nezhad2024genotypicvariantsof pages 1-2, novelli2024autosomalrecessiveguanosine pages 1-2)

Table: This table summarizes the principal inherited genetic causes grouped under disorders of catecholamine synthesis/biogenic amine disorders, emphasizing pathway role, diagnostic biochemical signatures, phenotypes, inheritance, and recent references. It is useful as a compact disease-knowledge-base scaffold linking umbrella categories to specific genes and biomarkers.

Key evidence gaps (explicit)

  • DBH (dopamine β-hydroxylase) deficiency and PNMT deficiency: not well covered by retrievable full-text evidence in this run; droxidopa is referenced in clinical trial search results broadly but not linked to primary DBH-deficiency cohorts in the retrieved evidence set.
  • Granular variant-level details (ClinVar classifications, gnomAD frequencies): not retrievable with the available tools in this run.
  • OMIM/Orphanet/ICD/MeSH cross-IDs: not retrievable with the available tools in this run.

References

  1. (hubschmann2021insightsintothe pages 1-2): Oya Kuseyri Hübschmann, Gabriella Horvath, Elisenda Cortès-Saladelafont, Yılmaz Yıldız, Mario Mastrangelo, Roser Pons, Jennifer Friedman, Saadet Mercimek-Andrews, Suet-Na Wong, Toni S. Pearson, Dimitrios I. Zafeiriou, Jan Kulhánek, Manju A. Kurian, Eduardo López-Laso, Mari Oppebøen, Sebile Kılavuz, Tessa Wassenberg, Helly Goez, Sabine Scholl-Bürgi, Francesco Porta, Tomáš Honzík, René Santer, Alberto Burlina, H. Serap Sivri, Vincenzo Leuzzi, Georg F. Hoffmann, Kathrin Jeltsch, Daniel Hübschmann, Sven F. Garbade, Birgit Assmann, Cheuk-Wing Fung, Philipp Guder, Stacey Tay Kiat Hong, Daniela Karall, Mitsuhiro Kato, Ivana Kavecan, Jeanette Aimee Koht, Alice Kuster, Thomas Lücke, Filippo Manti, Pablo Mir, Chris Mühlhausen, Halise Neslihan Önenli Mungan, Natalia Alexandra Julia Palacios, Joaquín Alejandro Fernández Ramos, Dora Steel, Galina Stevanović, Jolanta Sykut-Cegielska, Marcel M. Verbeek, Angeles García-Cazorla, and Thomas Opladen. Insights into the expanding phenotypic spectrum of inherited disorders of biogenic amines. Nature Communications, Sep 2021. URL: https://doi.org/10.1038/s41467-021-25515-5, doi:10.1038/s41467-021-25515-5. This article has 49 citations and is from a highest quality peer-reviewed journal.

  2. (OpenTargets Search: aromatic L-amino acid decarboxylase deficiency,tyrosine hydroxylase deficiency,dopamine beta-hydroxylase deficiency): Open Targets Query (aromatic L-amino acid decarboxylase deficiency,tyrosine hydroxylase deficiency,dopamine beta-hydroxylase deficiency, 6 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  3. (chu2024genetherapyfor pages 1-2): Wing Sum Chu, Joanne Ng, Simon N. Waddington, and Manju A. Kurian. Gene therapy for neurotransmitter‐related disorders. Journal of Inherited Metabolic Disease, 47:176-191, Jan 2024. URL: https://doi.org/10.1002/jimd.12697, doi:10.1002/jimd.12697. This article has 13 citations and is from a peer-reviewed journal.

  4. (paola2024aromaticlaminoacid pages 2-3): Sandro Santa Paola, Francesco Domenico Di Blasi, Eugenia Borgione, Mariangela Lo Giudice, Marika Giuliano, Rosa Pettinato, Vincenzo Di Stefano, Filippo Brighina, Antonino Lupica, and Carmela Scuderi. Aromatic l-amino acid decarboxylase deficiency: a genetic screening in sicilian patients with neurological disorders. Genes, 15:134, Jan 2024. URL: https://doi.org/10.3390/genes15010134, doi:10.3390/genes15010134. This article has 2 citations.

  5. (reyes2023diagnosisofautism pages 1-2): Zoe Maria Dominique Reyes, Emma Lynch, Julia Henry, Lenika Marina De Simone, and Sarah A. Sobotka. Diagnosis of autism in a rare case of tyrosine hydroxylase deficiency: a case report. BMC Medical Genomics, Apr 2023. URL: https://doi.org/10.1186/s12920-023-01510-1, doi:10.1186/s12920-023-01510-1. This article has 4 citations and is from a peer-reviewed journal.

  6. (nezhad2024genotypicvariantsof pages 1-2): Seyed Reza Kazemi Nezhad, Pegah Namdar Aligoodarzi, Golale Rostami, Gholamreza Shariati, Hamid Galehdari, Alihossein Saberi, Alireza Sedaghat, and Mohammad Hamid. Genotypic variants of the tetrahydrobiopterin (bh4) biosynthesis genes in patients with hyperphenylalaninemia from different regions of iran. Molecular Genetics & Genomic Medicine, Oct 2024. URL: https://doi.org/10.1002/mgg3.2294, doi:10.1002/mgg3.2294. This article has 5 citations and is from a peer-reviewed journal.

  7. (novelli2024autosomalrecessiveguanosine pages 1-2): Maria Novelli, Manuela Tolve, Vicente Quiroz, Claudia Carducci, Rossella Bove, Giacomina Ricciardi, Kathryn Yang, Filippo Manti, Francesco Pisani, Darius Ebrahimi‐Fakhari, Serena Galosi, and Vincenzo Leuzzi. Autosomal recessive guanosine triphosphate cyclohydrolase i deficiency: redefining the phenotypic spectrum and outcomes. Movement Disorders Clinical Practice, 11:1072-1084, Jul 2024. URL: https://doi.org/10.1002/mdc3.14157, doi:10.1002/mdc3.14157. This article has 5 citations and is from a peer-reviewed journal.

  8. (paola2024aromaticlaminoacid pages 1-2): Sandro Santa Paola, Francesco Domenico Di Blasi, Eugenia Borgione, Mariangela Lo Giudice, Marika Giuliano, Rosa Pettinato, Vincenzo Di Stefano, Filippo Brighina, Antonino Lupica, and Carmela Scuderi. Aromatic l-amino acid decarboxylase deficiency: a genetic screening in sicilian patients with neurological disorders. Genes, 15:134, Jan 2024. URL: https://doi.org/10.3390/genes15010134, doi:10.3390/genes15010134. This article has 2 citations.

  9. (NCT01395641 chunk 1): A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC. National Taiwan University Hospital. 2014. ClinicalTrials.gov Identifier: NCT01395641

  10. (NCT04903288 chunk 1): A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants. PTC Therapeutics. 2021. ClinicalTrials.gov Identifier: NCT04903288

  11. (mai2025framelessintraputaminaldelivery pages 1-2): Roni Mai, Dmitriy Reshchikov, Vladimir Popov, Sergey Gorelikov, Ekaterina Zakharova, and Svetlana Mikhaylova. Frameless intraputaminal delivery of gene therapy with eladocagene exuparvovec in patients with aromatic l-amino acid decarboxylase deficiency: safe and efficient results. Child's Nervous System, Nov 2025. URL: https://doi.org/10.1007/s00381-025-07020-y, doi:10.1007/s00381-025-07020-y. This article has 1 citations.

  12. (deng2025centralbiogenicamine pages 1-2): Isaac Bul Deng, Jordan Follett, Jesse D. Fox, Shannon Wall, and Matthew J. Farrer. Central biogenic amine deficiency with concomitant exploratory behavioral deficits in dnajc12 knock-out mice. NPJ Parkinson's Disease, May 2025. URL: https://doi.org/10.1038/s41531-025-00991-4, doi:10.1038/s41531-025-00991-4. This article has 2 citations and is from a domain leading peer-reviewed journal.

  13. (deng2024dnajc12inmonoamine pages 1-5): Isaac Bul Deng, Jordan Follett, Mengfei Bu, and Matthew J. Farrer. Dnajc12 in monoamine metabolism, neurodevelopment, and neurodegeneration. Movement Disorders, 39:249-258, Nov 2024. URL: https://doi.org/10.1002/mds.29677, doi:10.1002/mds.29677. This article has 17 citations and is from a highest quality peer-reviewed journal.

  14. (sentieri2023analisideilivelli pages 21-25): E Sentieri. Analisi dei livelli di 3-omd su dbs nella popolazione neonatale ligure: verso lo screening di aadcd. Unknown journal, 2023.

  15. (lee2024apositionstatement pages 1-2): Hui-Min Lee, Saadet Mercimek-Andrews, Gabriella Horvath, Diana Marchese, Richard E. Poulin, Alexis Krolick, Kati-Lyn Tierney, Jasmine Turna, Judy Wei, and Wuh-Liang Hwu. A position statement on the post gene-therapy rehabilitation of aromatic i-amino acid decarboxylase deficiency patients. Orphanet Journal of Rare Diseases, Jan 2024. URL: https://doi.org/10.1186/s13023-024-03019-x, doi:10.1186/s13023-024-03019-x. This article has 10 citations and is from a peer-reviewed journal.

  16. (roubertie2024genetherapyfor media e0e2cf3d): Agathe Roubertie, Thomas Opladen, Heiko Brennenstuhl, Oya Kuseyri Hübschmann, Lisa Flint, Michel A. Willemsen, Vincenzo Leuzzi, Angels Garcia Cazorla, Manju A. Kurian, Marie Céline François‐Heude, Paul Hwu, Bruria Ben Zeev, Karl Kiening, Thomas Roujeau, Roser Pons, and Toni S. Pearson. Gene therapy for aromatic l‐amino acid decarboxylase deficiency: requirements for safe application and knowledge‐generating follow‐up. Journal of Inherited Metabolic Disease, 47:463-475, Jul 2024. URL: https://doi.org/10.1002/jimd.12649, doi:10.1002/jimd.12649. This article has 27 citations and is from a peer-reviewed journal.

  17. (deng2025centralbiogenicamine pages 2-4): Isaac Bul Deng, Jordan Follett, Jesse D. Fox, Shannon Wall, and Matthew J. Farrer. Central biogenic amine deficiency with concomitant exploratory behavioral deficits in dnajc12 knock-out mice. NPJ Parkinson's Disease, May 2025. URL: https://doi.org/10.1038/s41531-025-00991-4, doi:10.1038/s41531-025-00991-4. This article has 2 citations and is from a domain leading peer-reviewed journal.

  18. (roubertie2024genetherapyfor pages 4-4): Agathe Roubertie, Thomas Opladen, Heiko Brennenstuhl, Oya Kuseyri Hübschmann, Lisa Flint, Michel A. Willemsen, Vincenzo Leuzzi, Angels Garcia Cazorla, Manju A. Kurian, Marie Céline François‐Heude, Paul Hwu, Bruria Ben Zeev, Karl Kiening, Thomas Roujeau, Roser Pons, and Toni S. Pearson. Gene therapy for aromatic l‐amino acid decarboxylase deficiency: requirements for safe application and knowledge‐generating follow‐up. Journal of Inherited Metabolic Disease, 47:463-475, Jul 2024. URL: https://doi.org/10.1002/jimd.12649, doi:10.1002/jimd.12649. This article has 27 citations and is from a peer-reviewed journal.

  19. (roubertie2024genetherapyfor media d99c2658): Agathe Roubertie, Thomas Opladen, Heiko Brennenstuhl, Oya Kuseyri Hübschmann, Lisa Flint, Michel A. Willemsen, Vincenzo Leuzzi, Angels Garcia Cazorla, Manju A. Kurian, Marie Céline François‐Heude, Paul Hwu, Bruria Ben Zeev, Karl Kiening, Thomas Roujeau, Roser Pons, and Toni S. Pearson. Gene therapy for aromatic l‐amino acid decarboxylase deficiency: requirements for safe application and knowledge‐generating follow‐up. Journal of Inherited Metabolic Disease, 47:463-475, Jul 2024. URL: https://doi.org/10.1002/jimd.12649, doi:10.1002/jimd.12649. This article has 27 citations and is from a peer-reviewed journal.

  20. (kulhanek2026studyofdiagnostica pages 46-49): J Kulhánek. Study of diagnostic and clinical aspects of selected inherited metabolic diseases. Unknown journal, 2026.

  21. (roubertie2024genetherapyfor pages 3-3): Agathe Roubertie, Thomas Opladen, Heiko Brennenstuhl, Oya Kuseyri Hübschmann, Lisa Flint, Michel A. Willemsen, Vincenzo Leuzzi, Angels Garcia Cazorla, Manju A. Kurian, Marie Céline François‐Heude, Paul Hwu, Bruria Ben Zeev, Karl Kiening, Thomas Roujeau, Roser Pons, and Toni S. Pearson. Gene therapy for aromatic l‐amino acid decarboxylase deficiency: requirements for safe application and knowledge‐generating follow‐up. Journal of Inherited Metabolic Disease, 47:463-475, Jul 2024. URL: https://doi.org/10.1002/jimd.12649, doi:10.1002/jimd.12649. This article has 27 citations and is from a peer-reviewed journal.

  22. (NCT05765981 chunk 1): An Early Clinical Trial to Evaluate VGN-R09b for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.. Shanghai Jiao Tong University School of Medicine. 2023. ClinicalTrials.gov Identifier: NCT05765981

  23. (NCT02852213 chunk 1): Krzysztof Bankiewicz. A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients. Krzysztof Bankiewicz. 2016. ClinicalTrials.gov Identifier: NCT02852213